Cardigan

Venbrook Strengthens Management Team, Promotes Brenda Sherman To Executive Vice President Of Business Development And Strategic Alliances

Retrieved on: 
Wednesday, March 8, 2023
Sherman, Insurance, LOS, Cardigan, Liberty Mutual, Business development, AIG

LOS ANGELES, March 8, 2023 /PRNewswire/ -- Venbrook Group, LLC ("Venbrook"), one of the largest independent insurance distribution and services firms in the U.S., today announced the promotion of Brenda Sherman as Executive Vice President of Business Development and Strategic Alliances. 

Key Points: 
  • A Venbrook executive since 2015, Sherman brings more than 30 years of industry experience across both the carrier and program administration sides.
  • In the newly created role, she will leverage her underwriting expertise and Venbrook's program platform to ramp up business development initiatives and work with agency partners to source alternative distribution channels.
  • Prior to joining Venbrook, Sherman held roles at AIG, Tokio Marine, Liberty Mutual, and others.
  • "Brenda is a valuable part of the Venbrook family and has a deep and unique understanding of our business model," said Jason D. Turner, Venbrook founder and CEO.

LILYSILK Unveils 2022 Fall Collection, Themed "Safari Style: An Expedition in Silk"

Retrieved on: 
Tuesday, August 23, 2022
CEO, Collection, Cardigan, Ultra, Multimedia, Instagram, Scarf, Flare, Hot Rap Songs, Fashion, Silk, Silk, Facebook

LOS ANGELES, Aug. 23, 2022 /PRNewswire/ -- LILYSILK, the world's leading silk brand with a mission to inspire people to live spectacular, sustainable lives, revealed its 2022 Fall Collection today.

Key Points: 
  • LOS ANGELES, Aug. 23, 2022 /PRNewswire/ -- LILYSILK, the world's leading silk brand with a mission to inspire people to live spectacular, sustainable lives, revealed its 2022 Fall Collection today.
  • Titled "Safari Style: An Expedition in Silk", the Collection is an exploration in style with chic safari-inspired silk and timeless utilitarian silhouettes crafted for city life.
  • This fall, we've taken our team's expertise and are thrilled to translate this with different variations of elegant, stylish, classic yet functional garments for modern women," said David Wang, CEO of LILYSILK company.
  • The Louisville Print, which draws inspiration from the American Louisville Equestrian, is a new print being introduced this fall.

LILYSILK Unveils 2022 Fall Collection, Themed "Safari Style: An Expedition in Silk"

Retrieved on: 
Tuesday, August 23, 2022
CEO, Collection, Cardigan, Ultra, Instagram, Scarf, Flare, Hot Rap Songs, Fashion, Silk, Silk, Facebook

LOS ANGELES, Aug. 23, 2022 /PRNewswire/ -- LILYSILK, the world's leading silk brand with a mission to inspire people to live spectacular, sustainable lives, revealed its 2022 Fall Collection today.

Key Points: 
  • LOS ANGELES, Aug. 23, 2022 /PRNewswire/ -- LILYSILK, the world's leading silk brand with a mission to inspire people to live spectacular, sustainable lives, revealed its 2022 Fall Collection today.
  • Titled "Safari Style: An Expedition in Silk", the Collection is an exploration in style with chic safari-inspired silk and timeless utilitarian silhouettes crafted for city life.
  • The Louisville Print, which draws inspiration from the American Louisville Equestrian, is a new print being introduced this fall.
  • For more information, visit www.lilysilk.com and follow @lilysilk on Instagram and @Lilysilk on Facebook.

Brickell Biotech Announces Positive Topline Results, Achieving Statistical Significance on all Primary and Secondary Endpoints, from Both U.S. Phase 3 Pivotal Clinical Studies of Sofpironium Bromide Gel, 15% in Primary Axillary Hyperhidrosis Patients

Retrieved on: 
Thursday, October 7, 2021
Intellectual property, Incidence, Headache, Cardigan, Nervous system, Autoimmunity, University of Florida, Hyperhidrosis, Conference, COVID-19, Graduate, Constipation, Duane syndrome, Blood, Time, Webcast, Urinary retention, Sweatpants, Population, SEC, Humanitarian use licenses, Anticholinergic, Xerostomia, Șaeș, Prevalence, Common, Nature, University, Acetylcholine, II, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Policy, Exocrine gland, Research, Therapy, Mydriasis, Leadership, Patient, Medical device, Pharmaceutical industry

BOULDER, Colo., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, today announced positive topline results from the Phase 3 pivotal Cardigan I and Cardigan II studies, which evaluated sofpironium bromide gel, 15% as a once daily topical formulation in patients with primary axillary hyperhidrosis (excessive underarm sweating).

Key Points: 
  • Overall, 89% of patients who were randomized to sofpironium gel, 15% in the studies completed the full six weeks of treatment.
  • Five (2.9%) and nine (5.0%) subjects who received sofpironium bromide gel, 15%, discontinued the Cardigan I and II studies, respectively, due to a TEAE.
  • The dial-in number for the conference call is 1-877-705-6003 for domestic participants and 1-201-493-6725 for international participants, with Conference ID #13723931.
  • A live webcast of the conference call can be accessed here or through the Investors tab on the Brickell Biotech website at https://www.brickellbio.com .

Brickell Biotech Announces Final Patient Completed Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Retrieved on: 
Monday, August 16, 2021
Time, II, Intellectual property, Blood, Population, Clinical trial, University of Florida, Anticholinergic, Sweatpants, Exocrine gland, Company, Private Securities Litigation Reform Act, Safety, University, COVID-19, GLOBE, Research, Nervous system, Hyperhidrosis, BBI, SEC, NDA, U.S. Securities and Exchange Commission, Cardigan, Patient, Leadership, Development, Humanitarian use licenses, Nasdaq, Therapy, Acetylcholine, GSP, Prevalence, Graduate, Pharmaceutical industry

BOULDER, Colo., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that the final patient has completed the Phase 3 pivotal Cardigan II study, which is evaluating sofpironium bromide gel, 15% in patients with primary axillary (underarm) hyperhidrosis. The Company expects to announce topline results for the U.S. Phase 3 pivotal Cardigan I and Cardigan II studies concurrently in the fourth quarter of 2021. Pending the outcome of these studies, the Company expects to submit a New Drug Application (NDA) for sofpironium bromide gel, 15% to the U.S. FDA in mid-2022.

Key Points: 
  • Were excited to announce that all patients have now completed their final visits in the Cardigan I and Cardigan II studies of sofpironium bromide gel, 15% in patients with primary axillary hyperhidrosis.
  • Phase 3 clinical program for sofpironium bromide gel, 15% is comprised of two pivotal clinical studies, Cardigan I and Cardigan II.
  • Each study has enrolled approximately 350 subjects nine years of age and older with primary axillary hyperhidrosis.
  • The studies are multicenter, randomized, double-blinded, vehicle (placebo)-controlled studies evaluating the efficacy and safety of topically applied sofpironium bromide gel, 15%.

Brickell Biotech Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 12, 2021
Income, Time, Trial of the century, II, Intellectual property, Blood, Awareness, Population, Clinical trial, University of Florida, Anticholinergic, Sweatpants, Research, Exocrine gland, Company, Private Securities Litigation Reform Act, University, COVID-19, GLOBE, Forgiveness, Hyperhidrosis, BBI, SEC, Pharmacokinetics, NDA, Nervous system, FDA, U.S. Securities and Exchange Commission, Conference, Cardigan, Patient, Leadership, Perspiration, Humanitarian use licenses, PK, Nasdaq, Safety, Therapy, Acetylcholine, Prevalence, Graduate, Pharmaceutical industry

BOULDER, Colo., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced financial results for the second quarter ended June 30, 2021 and provided a corporate update.

Key Points: 
  • Research and development expenses were $8.8million for the second quarter of 2021, compared to $2.7million for the second quarter of 2020.
  • General and administrative expenses were $2.9million for the second quarter of 2021, compared to $3.0million for the second quarter of 2020.
  • Total other income, net was $0.4million for the second quarter of 2021, compared to $7thousand for the second quarter of 2020.
  • Brickells net loss was $11.1million for the second quarter of 2021 compared to $5.1million for the second quarter of 2020.

Duluth Trading Co. Debuts The 'Workday Warrior' Wardrobe

Retrieved on: 
Tuesday, August 27, 2019
Culture, Decades, Clothing, Duluth Trading Company, Workwear, Sweater, Cardigan

The new 'Workday Warrior' collection redefines workwear with Duluth Trading's better-built ingenuity.

Key Points: 
  • The new 'Workday Warrior' collection redefines workwear with Duluth Trading's better-built ingenuity.
  • The Workday Warrior Collection adopts a mix-and-match wardrobe approach with key principles in mind: functionality, performance and style.
  • The line includes products such as the Shiftless Cardigan Sweater, the Wrinklefighter Button-Up Shirt and DuluthFlex Daily Denim.
  • "We have been working to redefine workwear by studying the life demands of our customers and listening to their wants and needs," said Stephanie Okada, Product Developer at Duluth Trading.

The Cardigans Announce Remastered Vinyl Re-Issue Of First Band On The Moon Featuring Hit Song "Love Fool" Available February 1st

Retrieved on: 
Friday, February 1, 2019
Albums, Musicians, Songs, The Cardigans, First Band on the Moon, Magnus Sveningsson, Rise and Shine, Lovefool, Peter Svensson, Shine, Cardigan, The Other Side of the Moon

In October 1992, bonded by their mutual love of hard rock music, guitarist Peter Svensson and bassist Magnus Sveningsson conceived The Cardigans.

Key Points: 
  • In October 1992, bonded by their mutual love of hard rock music, guitarist Peter Svensson and bassist Magnus Sveningsson conceived The Cardigans.
  • After an early recording of "Rise & Shine" appeared on a local independent label in 1994, The Cardigans were swiftly signed to Stockholm Records.
  • The rise of The Cardigans has since been gradual, allowing them the time to develop naturally as their sales and positive exposure grew with each release.
  • Prior to the 'First Band On The Moon' album in September 1996, The Cardigans released "Lovefool."